

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 March 2003 (06.03.2003)

PCT

(10) International Publication Number
WO 03/018556 A1

(51) International Patent Classification⁷: C07D 211/06,
409/12, 401/12, A61K 31/445, A61P 37/00, 11/06, 31/16

MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/SE02/01401

(22) International Filing Date: 19 July 2002 (19.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0117899.5 23 July 2001 (23.07.2001) GB

(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): EVANS, Richard
[GB/GB]; AstraZeneca R & D Charnwood, Bakewell
Road, Loughborough, Leicestershire LE11 5RH (GB).
PERRY, Matthew [GB/GB]; AstraZeneca R & D Charn-
wood, Bakewell Road, Loughborough, Leicestershire
LE11 5RH (GB). SPRINGTHORPE, Brian [GB/GB];
AstraZeneca R & D Charnwood, Bakewell Road, Lough-
borough, Leicestershire LE11 5RH (GB).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; As-
traZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW);
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG)
— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

(57) Abstract: The invention provides compounds of formula (I): [Chemical formula should be inserted here. Please see paper copy]
wherein: T is C(O) or S(O)₂; W is C(O) or S(O)₂; X is CH₂, O or NH; Y is CR₁₁ or N; n is 0, 1 or 2; m is 1 or, when Y is CR₁₁ m is 0;
R₁ is optionally substituted aryl or optionally substituted heterocyclyl; R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are, independently, hydrogen or
C71-6#191 alkyl; R₉ is hydrogen or C₁-C₆ alkyl; R₁₀ is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally
substituted heterocyclyl; and R₁₁ is hydrogen or C₁-C₆ alkyl; that are modulators of chemokine (especially CCR3) activity and are
especially useful for treating asthma and/or rhinitis.

BEST AVAILABLE COPY

WO 03/018556 A1

Piperidine derivatives useful as modulators of chemokine receptor activity.

The present invention concerns piperidine derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.

Pharmaceutically active piperidine derivatives are disclosed in WO99/38514, WO99/04794 and WO00/35877.

Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a rôle in the maturation of cells of the immune system. Chemokines play an important rôle in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif. The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C-X-C, or α) and Cys-Cys (C-C, or β) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β).


Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

Histamine is a basic amine, 2-(4-imidazolyl)-ethylamine, and is formed from histidine by histidine decarboxylase. It is found in most tissues of the body, but is present

in high concentrations in the lung, skin and in the gastrointestinal tract. At the cellular level inflammatory cells such as mast cells and basophils store large amounts of histamine. It is recognised that the degranulation of mast cells and basophils and the subsequent release of histamine is a fundamental mechanism responsible for the clinical manifestation of an allergic process. Histamine produces its actions by an effect on specific histamine G-protein coupled receptors, which are of three main types, H1, H2 and H3. Histamine H1 antagonists comprise the largest class of medications used in the treatment of patients with allergic disorders, especially rhinitis and urticaria. Antagonists of H1 are useful in controlling the allergic response by for example blocking the action of histamine on post-capillary venule smooth muscle, resulting in decreased vascular permeability, exudation and oedema. The antagonists also produce blockade of the actions of histamine on the H1 receptors on c-type nociceptive nerve fibres, resulting in decreased itching and sneezing.

Viral infections are known to cause lung inflammation. It has been shown experimentally that the common cold increases mucosal output of eotaxin in the airways. Instillation of eotaxin into the nose can mimic some of the signs and symptoms of a common cold. (See, Greiff L *et al* Allergy (1999) 54(11) 1204-8 [Experimental common cold increase mucosal output of eotaxin in atopic individuals] and Kawaguchi M *et al* Int. Arch. Allergy Immunol. (2000) 122 S1 44 [Expression of eotaxin by normal airway epithelial cells after virus A infection].)

The present invention provides a compound of formula (I):



wherein:

T is C(O) or S(O)₂;

W is C(O) or S(O)₂;

X is CH₂, O or NH;

Y is CR¹¹ or N;

n is 0, 1 or 2;

m is 1 or, when Y is CR¹¹ m is 0;

R¹ is optionally substituted aryl or optionally substituted heterocyclyl;

- $R^2, R^3, R^4, R^5, R^6, R^7$ and R^8 are, independently, hydrogen or C_{1-6} alkyl; wherein these alkyl groups are optionally substituted by OH, provided that when Y is N then R^8 does not have a hydroxy on the carbon atom bonded to Y;
or R^2 and R^3, R^4 and R^5 , or R^6 and R^7 , together with the atom to which they are attached,
5 form a 3-7 membered carbocyclic ring;
 R^4 may additionally be OH or C_{1-6} alkoxy;
when Y is CR^{11} the group R^6 may additionally be OH or C_{1-6} alkoxy;
provided that only one R^4 or R^6 is OH;
 R^9 is hydrogen or C_{1-6} alkyl;
- 10 R^{10} is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;
 R^{11} is hydrogen or C_{1-6} alkyl;
wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by:
halogen, cyano, nitro, hydroxy, oxo, $S(O)_p R^{12}$, $OC(O)NR^{13}R^{14}$, $NR^{15}R^{16}$, $NR^{17}C(O)R^{18}$,
15 $NR^{19}C(O)NR^{20}R^{21}$, $S(O)_2NR^{22}R^{23}$, $NR^{24}S(O)_2R^{25}$, $C(O)NR^{26}R^{27}$, $C(O)R^{28}$, CO_2R^{29} ,
 $NR^{30}CO_2R^{31}$, C_{1-6} alkyl, CF_3 , C_{1-6} alkoxy(C_{1-6})alkyl, C_{1-6} alkoxy, OCF_3 , C_{1-6} alkoxy(C_{1-6})alkoxy (preferably not in the form of an acetal), C_{1-6} alkylthio, C_{2-6} alkenyl, C_{2-6} alkynyl,
 C_{3-10} cycloalkyl (itself optionally substituted by C_{1-4} alkyl or oxo), methylenedioxy,
difluoromethylenedioxy, phenyl, phenyl(C_{1-4})alkyl, phenoxy, phenylthio, phenyl(C_{1-4})alkoxy, heteroaryl, heteroaryl(C_{1-4})alkyl, heteroaryloxy or heteroaryl(C_{1-4})alkoxy;
20 wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halogen, hydroxy, nitro, $S(O)_q(C_{1-4}$ alkyl), $S(O)_2NH_2$, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), CO_2H , $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3 ;
- 25 p and q are, independently, 0, 1 or 2;
 $R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22}, R^{23}, R^{24}, R^{26}, R^{27}, R^{28}, R^{29}$, and R^{30} are,
independently, hydrogen, C_{1-6} alkyl (optionally substituted by halogen, hydroxy or C_{3-10} cycloalkyl), $CH_2(C_{2-6}$ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy,
nitro, NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl) $_2$, $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$
30 alkyl), $S(O)_2N(C_{1-4}$ alkyl) $_2$, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl),
 $C(O)N(C_{1-4}$ alkyl) $_2$, CO_2H , $CO_2(C_{1-4}$ alkyl), $NHC(O)(C_{1-4}$ alkyl), $NHS(O)_2(C_{1-4}$ alkyl),
 $C(O)(C_{1-4}$ alkyl), CF_3 or OCF_3) or heterocyclyl (itself optionally substituted by halogen,
hydroxy, nitro, NH_2 , $NH(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl) $_2$, $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$,

S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃;
alternatively NR¹³R¹⁴, NR¹⁵R¹⁶, NR²⁰R²¹, NR²²R²³, NR²⁶R²⁷, and N(C₁₋₄ alkyl)₂ may,

5 independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine, 1,4-morpholine or 1,4-piperazine, the latter optionally substituted by C₁₋₄alkyl on the distal nitrogen;

R¹², R²⁵ and R³¹ are, independently, C₁₋₆ alkyl (optionally substituted by halogen, hydroxy or C₃₋₁₀ cycloalkyl), CH₂(C₂₋₆ alkenyl), phenyl (itself optionally substituted by halogen,
10 hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and R¹⁴ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and R¹⁴ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and
15 R¹⁴ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and R¹⁴ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³
20 and R¹⁴ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and R¹⁴ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃);

or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

25 Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present invention covers all such isomers and mixtures thereof in all proportions.

Suitable salts include acid addition salts such as a hydrochloride, dihydrochloride, hydrobromide, phosphate, sulfate, acetate, diacetate, fumarate, maleate, tartrate, citrate,
30 oxalate, methanesulfonate or *p*-toluenesulfonate. Salts also include metal salts, such as alkali metal salts (for example a sodium salt).

The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.

Halogen includes fluorine, chlorine, bromine and iodine.

Alkyl groups and moieties are straight or branched chain and are, for example, methyl, ethyl, n-propyl, iso-propyl or tert-butyl. The term 'butyl' without any indication of branching is a straight chain (that is n-butyl).

5 Alkenyl is, for example, vinyl or allyl.

Alkynyl is, for example, propargyl.

Haloalkyl is preferably CF₃. Haloalkoxy is preferably OCF₃.

10 Cycloalkyl is mono-, bi or tricyclic and is, for example, cyclopropyl, cyclopentyl, cyclohexyl, norbornyl or camphoryl. The cycloalkyl ring is optionally fused to a benzene ring (for example forming a bicyclo[4.2.0]octa-1,3,5-trienyl or indanyl ring system).

3-7 Membered carbocyclic rings are preferably monocyclic and include cyclopropyl, cyclopentyl and cyclohexyl.

Aryl is preferably phenyl or naphthyl.

Arylalkyl is, for example aryl(C₁₋₄)alkyl, such as benzyl or 2-phenylethyl.

15 Heterocyclyl is an aromatic or non-aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulfur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Heterocyclyl is, for example, furyl, thienyl (also known as thiophenyl), pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, piperidinyl, 20 morpholinyl, pyridinyl (for example in 6-oxo-1,6-dihydro-pyridinyl), pyrimidinyl, indolyl, 2,3-dihydroindolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), 2,3-dihydrobenz[b]thienyl (for example in 1,1-dioxo-2,3-dihydrobenz[b]thienyl), indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl (for example in 1H-benzthiazol-2-one-yl), 2,3-dihydrobenzthiazolyl (for 25 example in 2,3-dihydrobenzthiazol-2-one-yl), 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as imidazo[1,2a]pyridinyl), thieno[3,2-b]pyridin-6-yl 1,2,3-benzoxadiazolyl (also known as benzo[1,2,3]thiadiazolyl), 2,1,3-benzothiadiazolyl, benzofurazan (also known as 2,1,3-benzoxadiazolyl), quinoxaliny, dihydro-1-benzopyryliumyl (for example in a coumarinyl or a chromonyl), 3,4-dihydro-1H-2,1-benzothiazinyl (for example in 2-dioxo-30 3,4-dihydro-1H-2,1-benzothiazinyl), a pyrazolopyridine (for example 1H-pyrazolo[3,4-b]pyridinyl), a purine (for example in 3,7-dihydro-purin-2,6-dione-8-yl), quinolinyl, isoquinolinyl (for example in 2H-isoquinolin-1-one-yl), a naphthyridinyl (for example [1,6]naphthyridinyl or [1,8]naphthyridinyl or in 1H-[1,8]naphthyridin-4-one-yl), a

benzothiazinyl (for example in 4H-benzo[1,4]thiazin-3-one-yl), benzo[d]imidazo[2,1-b]thiazol-2-yl or dibenzothiophenyl (also known as dibenzothiényl); or an N-oxide thereof (such as a pyridine N-oxide), or an S-oxide or S-dioxide thereof.

5 An N-oxide of a compound of formula (I) is, for example, a 1-oxido-piperidinyl compound.

The present invention provides a compound of formula (I) wherein, T is C(O) or S(O)₂; W is C(O) or S(O)₂; X is CH₂, O or NH; Y is CR¹¹ or N; n is 0, 1 or 2; m is 1 or, when Y is CR¹¹ m is 0; R¹ is optionally substituted aryl or optionally substituted heterocyclyl; R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are, independently, hydrogen or C₁₋₆ alkyl; wherein these alkyl groups are optionally substituted by OH, provided that when Y is N then R⁸ does not have a hydroxy on the carbon atom bonded to Y; or R² and R³, R⁴ and R⁵, or R⁶ and R⁷, together with the atom to which they are attached, form a 3-7 membered carbocyclic ring; R⁴ may additionally be OH or C₁₋₆ alkoxy; when Y is CR¹¹ the group R⁶ may additionally be OH or C₁₋₆ alkoxy; provided that only one R⁴ or R⁶ is OH; R⁹ is hydrogen or C₁₋₆ alkyl; R¹⁰ is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl; R¹¹ is hydrogen or C₁₋₆ alkyl; wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, cyano, nitro, hydroxy, oxo, S(O)_pR¹², OC(O)NR¹³R¹⁴, NR¹⁵R¹⁶, NR¹⁷C(O)R¹⁸, NR¹⁹C(O)NR²⁰R²¹, S(O)₂NR²²R²³, NR²⁴S(O)₂R²⁵, C(O)NR²⁶R²⁷, C(O)R²⁸, CO₂R²⁹, NR³⁰CO₂R³¹, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ alkoxy(C₁₋₆)alkoxy, C₁₋₆ alkylthio, C₁₋₆ haloalkylthio, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl (itself optionally substituted by C₁₋₄ alkyl or oxo), methylenedioxy, difluoromethylenedioxy, phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenylthio, phenyl(C₁₋₄)alkoxy, heteroaryl, heteroaryl(C₁₋₄)alkyl, heteroaryloxy or heteroaryl(C₁₋₄)alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halogen, hydroxy, nitro, S(O)_q(C₁₋₄ alkyl), S(O)₂NH₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃; p and q are, independently, 0, 1 or 2; R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁶, R²⁷, R²⁸, R²⁹, and R³⁰ are, independently, hydrogen, C₁₋₆ alkyl (optionally substituted by halogen, hydroxy or C₃₋₁₀ cycloalkyl), CH₂(C₂₋₆ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl),

NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃); alternatively NR¹³R¹⁴, NR¹⁵R¹⁶, NR²⁰R²¹, NR²²R²³, NR²⁶R²⁷, may, independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine, piperidine, azepine, 1,4-morpholine or 1,4-piperazine, the latter optionally substituted by C₁₋₄alkyl on the distal nitrogen; R¹², R²⁵ and R³¹ are, independently, C₁₋₆ alkyl (optionally substituted by halogen, hydroxy or C₃₋₁₀ cycloalkyl), CH₂(C₂₋₆ alkenyl), phenyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and R¹⁴ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and R¹⁴ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and R¹⁴ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and R¹⁴ above), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and R¹⁴ above), cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups may join to form a ring as described for R¹³ and R¹⁴ above), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃); or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

In another aspect X is O.

In another aspect R¹ is phenyl substituted with one or more of fluorine, chlorine, C₁₋₄ alkyl (especially methyl) or C₁₋₄ alkoxy (especially methoxy).

In a further aspect R¹ is phenyl optionally substituted (for example with one, two or three of) by halogen (especially fluoro or chloro), C₁₋₄ alkyl (especially methyl) or C₁₋₄ alkoxy (especially methoxy). In a still further aspect R¹ is phenyl substituted by one, two or three of: fluoro, chloro, methyl or methoxy. In another aspect R¹ is phenyl optionally substituted by halogen (especially fluoro or chloro), C₁₋₄ alkyl (especially methyl);

especially optionally substituted (for example independently with one, two or three of, especially two or three of) by fluoro, chloro or methyl. In a still further aspect R^1 is 3,4-dichlorophenyl, or, additionally 2-chloro-4-fluorophenyl, 2-methyl-4-chlorophenyl, 2,4-dichloro-3-methylphenyl or 3,4-dichloro-2-methylphenyl.

5 In another aspect one of T and W is C(O) and the other is S(O)₂.

In a still further aspect T is C(O).

In another aspect W is S(O)₂.

In another aspect R^{11} is hydrogen.

In yet another aspect Y is CH or N. In one aspect Y is N. In another aspect Y is

10 CH.

In yet another aspect R^2 is hydrogen or methyl; for example R^2 is hydrogen.

In a further aspect R^3 is hydrogen.

In another aspect of the invention m is 0 or 1; especially 1.

In a still further aspect n is 0 or 1; n is especially 1.

15 In another aspect R^4 is hydrogen, methyl, ethyl or hydroxy; for example it is hydrogen or hydroxy.

In yet another aspect R^5 , R^6 and R^7 are, independently, hydrogen, methyl or ethyl (particularly hydrogen or methyl, for example they are all hydrogen).

In yet another aspect R^8 and R^9 are both hydrogen.

20 In a further aspect R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 and R^9 are all hydrogen.

In a still further aspect R^{10} is unsubstituted phenyl, mono-substituted phenyl, unsubstituted heterocyclyl or mono-substituted heterocyclyl, the substituents being chosen from those described above.

25 In another aspect R^{10} is phenyl substituted with halogen, alkyl or alkoxy; especially halogen (for example fluoro or chloro), C₁₋₄ alkyl (for example methyl) or C₁₋₄ alkoxy (for example methoxy).

30 In yet another aspect R^{10} is phenyl or heterocyclyl, either of which is optionally substituted by: halo, hydroxy, nitro, cyano, oxo, amino, C₁₋₄ alkyl (itself optionally substituted by S(O)₂(C₁₋₄ alkyl), S(O)₂phenyl), C₁₋₄ alkoxy, S(O)_kR³² (wherein k is 0, 1 or 2 (preferably 2); and R³² is C₁₋₄ alkyl, C₁₋₄ hydroxyalkyl, C₃₋₇ cycloalkyl(C₁₋₄ alkyl) (such as cyclopropylmethyl) or phenyl), C₁₋₄ haloalkylthio, C(O)NH₂, NHS(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl) or S(O)₂N(C₁₋₄ alkyl)₂.

In another aspect R^{10} is phenyl or heterocyclyl, either of which is optionally substituted by: halo, hydroxy, nitro, cyano, oxo, amino, C_{1-4} alkyl (itself optionally substituted by $S(O)_2(C_{1-4} \text{ alkyl})$, $S(O)_2\text{phenyl}$), C_{1-4} alkoxy, $S(O)_kR^{32}$ (wherein k is 0, 1 or 2 (preferably 2); and R^{32} is C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{3-7} cycloalkyl(C_{1-4} alkyl) (such as cyclopropylmethyl) or phenyl), $C(O)NH_2$, $NHS(O)_2(C_{1-4} \text{ alkyl})$, $S(O)_2NH_2$, $S(O)_2NH(C_{1-4} \text{ alkyl})$ or $S(O)_2N(C_{1-4} \text{ alkyl})_2$.

In one aspect the variable R^{10} is phenyl optionally substituted by: halo, hydroxy, nitro, cyano, amino, C_{1-4} alkyl (itself optionally substituted by $S(O)_2(C_{1-4} \text{ alkyl})$, $S(O)_2\text{phenyl}$), C_{1-4} alkoxy, $S(O)_kR^{32}$ (wherein k is 0, 1 or 2 (preferably 2); and R^{32} is C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{3-7} cycloalkyl(C_{1-4} alkyl) (such as cyclopropylmethyl) or phenyl), C_{1-4} haloalkylthio, $C(O)NH_2$, $NHS(O)_2(C_{1-4} \text{ alkyl})$, $S(O)_2NH_2$, $S(O)_2NH(C_{1-4} \text{ alkyl})$ or $S(O)_2N(C_{1-4} \text{ alkyl})_2$ (and these alkyl groups may join to form a ring as described for R^{13} and R^{14} above).

In another aspect the variable R^{10} is phenyl optionally substituted by: halo, hydroxy, nitro, cyano, amino, C_{1-4} alkyl (itself optionally substituted by $S(O)_2(C_{1-4} \text{ alkyl})$, $S(O)_2\text{phenyl}$), C_{1-4} alkoxy, $S(O)_kR^{32}$ (wherein k is 0, 1 or 2 (preferably 2); and R^{32} is C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{3-7} cycloalkyl(C_{1-4} alkyl) (such as cyclopropylmethyl) or phenyl), $C(O)NH_2$, $NHS(O)_2(C_{1-4} \text{ alkyl})$, $S(O)_2NH_2$, $S(O)_2NH(C_{1-4} \text{ alkyl})$ or $S(O)_2N(C_{1-4} \text{ alkyl})_2$ (and these alkyl groups may join to form a ring as described for R^{13} and R^{14} above).


In yet another aspect the variable R^{10} is phenyl optionally substituted by: halo, hydroxy, nitro, cyano, amino, C_{1-4} alkyl (itself optionally substituted by $S(O)_2\text{phenyl}$), C_{1-4} alkoxy, $S(O)_kR^{32}$ (wherein k is 0, 1 or 2; and R^{32} is C_{1-4} alkyl or phenyl) or C_{1-4} haloalkylthio.

In a further aspect the variable R^{10} is phenyl optionally substituted by: halo, hydroxy, nitro, cyano, amino, C_{1-4} alkyl (itself optionally substituted by $S(O)_2\text{phenyl}$), C_{1-4} alkoxy or $S(O)_kR^{32}$ (wherein k is 0, 1 or 2; and R^{32} is C_{1-4} alkyl or phenyl).

In a still further aspect the present invention provides a compound of formula (I) wherein R^{10} is phenyl optionally substituted by halogen (such as fluoro or chloro), C_{1-4} alkyl (for example methyl), CF_3 or $CO_2(C_{1-4} \text{ alkyl})$ (for example CO_2CH_3); {especially R^{10} substituted with halogen (for example chloro or fluoro) or C_{1-4} alkyl (for example methyl)}. The variable R^{10} may also be thienyl or pyridyl.


Compounds of formula (Ia), (Ia'), (Ib), (Ic) and (Id) are examples of compounds of formula (I).

In a still further aspect the present invention provides a compound of formula (Ia):




wherein: X, n, R¹, R⁴, R⁸, R⁹ and R¹⁰ are as defined above; or a pharmaceutically acceptable salt thereof.

5 In yet another aspect the present invention provides a compound of formula (Ia'):



wherein: X, n, R¹, R⁴, R⁶, R⁸, R⁹ and R¹⁰ are as defined above; or a pharmaceutically acceptable salt thereof.


In another aspect the present invention provides a compound of formula (Ib):



10


wherein: X, n, R¹, R⁴, R⁸, R⁹ and R¹⁰ are as defined above; or a pharmaceutically acceptable salt thereof.

In a further aspect the present invention provides a compound of formula (Ic):



15 wherein: X, n, R¹, R⁴, R⁹ and R¹⁰ are as defined above; or a pharmaceutically acceptable salt thereof.


In a still further aspect the present invention provides a compound of formula (Id):



wherein: X, n, R¹, R⁴, R⁹ and R¹⁰ are as defined above; or a pharmaceutically acceptable salt thereof.

The compounds of formula (I) (for example compounds of formula (Ia), (Ia'), (Ib), (Ic) and (Id)) can be prepared by adaptation of methods known in the art, by the methods
5 recited below or by methods analogous to the method of Example 1.


A compound of formula (I), wherein R⁹ is hydrogen, T is C(O) and Y is N, can be prepared by reacting a compound of formula (II):



with an isocyanate of formula R¹⁰WN=C=O in the presence of a suitable solvent at a
10 suitable temperature (such as room temperature). Isocyanates of formula R¹⁰WN=C=O are commercially available or can be prepared by optional adaptation of methods described in the literature.

Alternatively a compound of formula (I), wherein R⁹ is hydrogen, T is C(O) and Y is N, can be prepared by reacting a compound of formula (II) with the adduct formed
15 between p-nitrophenyl chloroformate and an amide R¹⁰WNH₂ in the presence of DMAP.

A compound of formula (II) can be prepared by deprotecting a compound of formula (III):




for example using trifluoroacetic acid in a suitable solvent (such as dichloromethane) or
20 using a source of hydrogen chloride in a suitable solvent (such as dioxane).

A compound of formula (III), wherein R² is hydrogen, can be prepared by reacting a compound of formula (IV):




with a compound of formula (V):

12



in the presence of $\text{NaBH}(\text{OAc})_3$ and acetic acid.


A compound of formula (III), wherein R^2 is C_{1-6} alkyl, can be prepared by reacting a compound of formula (XVII):



with a Grignard reagent of formula R^2MgHal (wherein Hal is chlorine, bromine or iodine) in a suitable solvent, such as tetrahydrofuran.


A compound of formula (XVII) can be prepared by reacting a compound of formula (IV) with a compound of formula (V) in the presence of titanium tetrakisopropoxide, for example in dichloroethane, followed by the addition of diethylaluminium cyanide to a solution, for example in toluene.

A compound of formula (I), wherein R^9 is hydrogen, T is $\text{S}(\text{O})_2$, W is $\text{C}(\text{O})$ and Y is N, can be prepared by reacting a compound of formula (IX):



with a compound of formula (II) in the presence of a suitable base (such as triethylamine) in a suitable solvent (such as tetrahydrofuran) at a suitable temperature (such as at, or below, room temperature). A compound of formula (IX) can be prepared by reacting an acid $\text{R}^{10}\text{CO}_2\text{H}$ with $\text{ClS}(\text{O})_2\text{N}=\text{C}=\text{O}$, for example below 80°C .


A compound of formula (I) wherein T and W are both $\text{S}(\text{O})_2$ and Y is N, can be prepared by reacting a compound of formula (X):



with a sulfonamide $\text{R}^{10}\text{S}(\text{O})_2\text{NHR}^9$ in the presence of a base (such as calcium oxide), in a suitable solvent (such as DMSO) at a temperature preferably in the range $50-110^\circ\text{C}$. (For

example see DE 1618439; DE 1249259; Chemical Abstracts 1967, 67, 116716a). A compound of formula (X) can be prepared by reacting a compound of formula (II) with $S(O)_2Cl_2$ in the presence of a suitable base (such as triethylamine).


- 5 A compound of formula (I) wherein T and W are both $S(O)_2$ and Y is N, can be prepared by reacting a compound of formula (Xa):



with a sulfonyl chloride $R^{10}SO_2Cl$ in the presence of a base (such as calcium oxide), in a suitable solvent (such as DMSO) at a temperature preferably in the range 50-110°C.


- 10 A compound of formula (I) wherein T is $S(O)_2$, W is CO and Y is N, can be prepared by reacting a compound of formula (Xa) with an acid $R^{10}COOH$ in the presence of an appropriate coupling agent (such as ethyl dimethylaminopropyl carbodiimide (EDCI), with 4-dimethylaminopyridine (DMAP) and 1-hydroxybenzotriazole (HOBT)) in a suitable solvent, for example DMF.

- 15 A compound of formula (I) wherein R^2 is hydrogen, T is C(O), W is $S(O)_2$ and Y is CR^{11} , can be prepared by firstly hydrolysing a compound of formula (XI):




- 20 wherein suitable ester groups include C_{1-6} alkyl groups, and reacting the product so formed with $R^{10}S(O)_2NHR^9$ in the presence of an appropriate coupling agent (such as ethyl dimethylaminopropyl carbodiimide (EDCI), with 4-dimethylaminopyridine (DMAP) and 1-hydroxybenzotriazole (HOBT)) in a suitable solvent, for example DMF.

A compound of formula (XI) where R^2 is H can be prepared by reductively aminating a compound of formula (XII):




14

with a compound of formula (XIII):




Alternatively a compound of formula (XI) where R^2 and R^3 are both H can be prepared by reaction of a compound of formula (XIIa):




with a compound of formula (XIII) in the presence of a base, for example potassium carbonate, in a suitable solvent, for example acetone at reflux.

Alternatively a compound of formula (XI) where R^2 and R^8 are H, n and m are 0 and Y is CR^{11} can be prepared by reaction of a compound of formula (XIIb):



with a compound of formula (XIII) in the presence of a base, for example sodium hydroxide, in a suitable solvent, for example THF, for example at room temperature.


A compound of formula (XI), wherein R^2 is C_{1-6} alkyl, can be prepared by reacting a compound of formula (XVIII):



with a Grignard reagent of formula R^2MgHal (wherein Hal is chlorine, bromine or iodine) in a suitable solvent, such as tetrahydrofuran.

A compound of formula (XVIII) can be prepared by reacting a compound of formula (XII) with a compound of formula (XIII) in the presence of titanium tetrakisopropoxide, for example in dichloroethane, followed by the addition of diethylaluminium cyanide to a solution, for example in toluene.


A compound of formula (I), wherein T and W are both $\text{C}(\text{O})$ and Y is CR^{11} , can be prepared by heating a compound of formula (XIV):



in the presence of $\text{R}^{10}\text{C}(\text{OR}')_2\text{N}(\text{CH}_3)_2$ or $\text{R}^{10}\text{C}(\text{OR}')_3$, wherein R' is methyl or ethyl, or $(\text{OR}')_3$ is $(\text{OCH}_2)_3\text{CCH}_3$. A compound of formula (XIV) can be prepared by firstly hydrolysing a compound of formula (XI) and then coupling the product so formed with an amine R^3NH_2 in the presence of an appropriate coupling agent (such as ethyl dimethylaminopropyl carbodiimide, with 4-dimethylaminopyridine and 1-hydroxybenzotriazole) in a suitable solvent, for example DMF.


A compound of formula (I) where R^9 is alkyl may be prepared by alkylation of a compound of formula (I) where R^9 is H by using an appropriate alkylating agent $\text{R}^9\text{-L}$, wherein L is a leaving group (such as triflate, a halide or a diazo group) in the presence of a suitable base (such as sodium hydride) in a suitable solvent.

A compound of formula (XV) can be prepared by reductively aminating a compound of formula (XVI):



with a compound of formula (IV) to obtain a compound wherein R^2 is hydrogen, or aminonitrile formation followed by a Grignard reaction to obtain a compound wherein R^2 is alkyl.



A compound of formula (XVI) can be prepared by reacting (when Y is CR^{11})



with Na_2SO_3 in aqueous acetone followed by activation of the sulfonic acid, for example by chlorination with POCl_3 and then reaction with an amine, R^9NH_2 .

When Y is N a compound of formula (XVI) can be obtained by heating a compound of formula (XVII):

16



with a compound of formula (XVIII), for example in dioxan, for example at reflux.

Further compounds of formula (I) can be prepared by adaptation of: the routes described above, methods described in the art or the Examples recited below. The intermediates identified above are commercially available or can be prepared by using or adapting methods described in the art.

In another aspect the present invention provides processes for the preparation of compound of formula (I) (for example compounds of formula (Ia), (Ia'), (Ib), (Ic) and (Id)).

The intermediates of formula (X) and (XV) defined herein are novel and these, and processes for their preparation, are provided as further features of the invention.

The compounds of the invention have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR3) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).

In one aspect examples of these conditions are:

- (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma (such as bronchial, allergic, intrinsic; extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); bronchitis (such as eosinophilic bronchitis); acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;

(2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behçet's disease, Sjogren's syndrome or systemic sclerosis;

5 (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;

(4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related
10 allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);

(5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or

15 (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, Sezary syndrome, idiopathic
20 thrombocytopenia pupura or disorders of the menstrual cycle.

The compounds of the invention are also H1 antagonists and may be used in the treatment of allergic disorders.

The compounds of the invention may also be used to control a sign and/or symptom of what is commonly referred to as a cold (for example a sign and/or symptom of a
25 common cold or influenza or other associated respiratory virus infection).

According to a further feature of the invention there is provided a compound of formula (I) (for example a compound of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).

30 According to a further feature of the present invention there is provided a method for modulating chemokine receptor activity (especially CCR3 receptor activity), or antagonising H1, in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the formula

(I) (for example a compound of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically acceptable salt thereof or a solvate thereof.

The invention also provides a compound of the formula (I) (for example a compound of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament.

In another aspect the invention provides the use of a compound of formula (I) (for example a compound of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (especially CCR3 receptor activity), or antagonising H1, in a warm blooded animal, such as man).

The invention further provides the use of a compound of formula (I) (for example a compound of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:

- (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma (such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); bronchitis (such as eosinophilic bronchitis); acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
- (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
- (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pheophigus, bullous Pheophigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
- (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related

allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);

(5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or

(6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle; in a warm blooded animal, such as man.

In a further aspect a compound of formula (I) (for example a compound of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma (such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)); or rhinitis (including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis).

In a still further aspect a compound of formula (I) (for example a compound of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma.

The present invention also provides the use of a compound of formula (I) (for example a compound of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of asthma or rhinitis.

The present invention further provides a method of treating a chemokine mediated disease state (especially a CCR3 mediated disease state, especially asthma) in a warm blooded mammal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I) (for example a compound

of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically acceptable salt thereof or solvate thereof.

In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR3 receptor) activity or antagonising H1, said ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) (for example a compound of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier. In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 0.1mg and 1g of active ingredient.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.

Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 0.01 mg kg^{-1} to 100 mg kg^{-1} of the compound, preferably in the range

of 0.1mgkg^{-1} to 20mgkg^{-1} of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I) (for example a compound of formula (Ia), (Ia'), (Ib), (Ic) or (Id)), or a pharmaceutically-acceptable salt thereof (hereafter Compound X), for therapeutic or prophylactic use in humans:

(a)

<u>Tablet I</u>	<u>mg/tablet</u>
Compound X	100
Lactose Ph.Eur.	179
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(b)

<u>Tablet II</u>	<u>mg/tablet</u>
Compound X	50
Lactose Ph.Eur.	229
Croscarmellose sodium	12.0
Polyvinylpyrrolidone	6
Magnesium stearate	3.0

(c)

<u>Tablet III</u>	<u>mg/tablet</u>
Compound X	1.0
Lactose Ph.Eur.	92
Croscarmellose sodium	4.0
Polyvinylpyrrolidone	2.0
Magnesium stearate	1.0

(d)

<u>Capsule</u>	<u>mg/capsule</u>
Compound X	10
Lactose Ph.Eur.	389
Croscarmellose sodium	100
Magnesium stearate	1.0

5

(e)

<u>Injection I</u>	<u>(50 mg/ml)</u>
Compound X	5.0% w/v
Isotonic aqueous solution	to 100%

Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β -cyclodextrin may be used to aid formulation.

10

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

The invention will now be illustrated by the following non-limiting Examples in which, unless stated otherwise:

15

(i) when given, ^1H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300MHz or 400MHz using perdeuterio DMSO-D6 (CD_3SOCD_3), methanol-D4 (CD_3OD) or CDCl_3 as the solvent unless otherwise stated;

- (ii) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected by electron impact (EI) or fast atom bombardment (FAB) or electrospray (ESI); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - $(M+H)^+$;
- (iii) the title and sub-title compounds of the examples and methods were named using the ACD/Index name program version 4.55 from Advanced Chemistry Development, Inc;
- (iv) unless stated otherwise, reverse phase HPLC was conducted using a Symmetry, NovaPak or Xterra reverse phase silica column; and
- (v) the following abbreviations are used:

RPHPLC	reverse phase HPLC	aq	aqueous
DMAP	dimethylaminopyridine	HOBT	1-hydroxybenzotriazole
EDCI	Ethyl dimethylaminopropyl carbodiimide		

Intermediate Preparation A

- This illustrates the preparation of (R) α -(aminomethyl)-4-(3,4-dichlorophenoxy)-1-piperidineethanol

a) (S) 2-[3-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]-2-hydroxypropyl]-1*H*-isoindole-1,3(2*H*)-dione

- (R) 2-(Oxiranylmethyl)-1*H*-isoindole-1,3(2*H*)-dione (Tetrahedron Asymmetry, 1996, 7, 1641, 5g) in a mixture of 50 ml of ethanol and 15 ml of DMF was treated with 4-(3,4-dichlorophenoxy)-piperidine (6g). The mixture was stirred overnight at room temperature. The solution was concentrated under vacuum and the residue was azeotroped twice with toluene. The crude material was purified by chromatography (ethyl acetate) to give the subtitle compound as a yellow oil.

- MS (APCI) 449/451 (MH^+)

1H NMR ($CDCl_3$) 7.92-7.81(2H, m); 7.77-7.70(2H, m); 7.30(1H, d); 6.98(1H, t); 6.74 (1H, dt); 4.34-4.20(1H, m); 4.09-3.97(1H, m); 3.83(1H, dd); 3.73(1H, dd); 2.93-2.79(1H, m); 2.73-2.60(1H, m); 2.59-2.37(3H, m); 2.31(1H, t); 2.02-1.86(2H, m); 1.86-1.67(2H, m).

b) (R) α -(Aminomethyl)-4-(3,4-dichlorophenoxy)-1-piperidineethanol

(S) 2-[3-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]-2-hydroxypropyl]-1*H*-isoindole-1,3(2*H*)-dione (4g) in ethanol (100ml) was treated with 20 ml of hydrazine monohydrate and the resulting mixture was refluxed for 3 hours. The reaction was cooled and filtered.

5 The filtrate was evaporated and the product was chromatographed (ethyl acetate) to give the title compound as a yellow oil which solidified on standing (2.5g).

MS (APCI) 319/321 (MH⁺)

¹H NMR (CDCl₃) 7.31(1H, d); 7.00(1H, d); 6.75 (1H, dd); 4.0(1H, app. Sept.); 3.74-3.62(1H, m); 2.94-2.84(1H, m); 2.82(1H, d); 2.72-2.61(1H, m); 2.65(1H, d); 2.60-2.49(1H, m); 2.46-2.21(3H, m); 2.06-1.901(2H, m); 1.90-1.72(2H, m).

Intermediate Preparation B

4-(3,4-dichlorophenoxy)-1-piperidinebutanoic acid hydrochloride

a) methyl 4-(3,4-dichlorophenoxy)-1-piperidinebutanoate

15 4-(3,4-Dichlorophenoxy)piperidine (4.15g) was dissolved in acetone (80ml).

Potassium carbonate (2.42g), sodium iodide (0.49g) and then methyl 4-bromobutyrate (1.95ml) were added and the mixture was stirred for 42h. The solvent was evaporated and the residue was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate. The organic phases were dried (MgSO₄), filtered and evaporated and the residue was chromatographed eluting with ethyl acetate : triethylamine (99:1) to give the subtitle compound (4.52g).

MS [M+H]⁺ (ES+) 346/348

¹H NMR (399.978 MHz) δ (CDCl₃) 1.73 - 1.82 (2H, m), 1.82 (2H, quintet), 1.92 - 2.00 (2H, m), 2.24 - 2.31 (2H, m), 2.35 (2H, t), 2.37 (2H, t), 2.67 - 2.74 (2H, m), 3.68 (3H, s), 4.21 - 4.29 (1H, m), 6.75 (1H, dd), 6.99 (1H, d), 7.30 (1H, d).

b) 4-(3,4-Dichlorophenoxy)-1-piperidinebutanoic acid hydrochloride

Methyl 4-(3,4-dichlorophenoxy)-1-piperidinebutanoate (0.48g) was dissolved in HCl solution (6M, 10mL) and methanol (1mL) was added. The reaction mixture was heated under reflux for 8 days. The solvents were evaporated to give the title compound (0.46g).

MS [M+H]⁺ (ES+) 332/334

An analytical sample was purified by HPLC (gradient ammonium acetate/acetonitrile 75% to 5% ;Xterra column) to give 4-(3,4-Dichlorophenoxy)-1-piperidinebutanoic acid:

¹H NMR (399.978 MHz) δ (CDCl₃) 1.87 (2H, quintet), 1.95 – 2.06 (2H, m), 2.08-2.18 (2H, m), 2.62 (2H, dt), 2.76 (2H, t), 2.89 (4H, s), 4.45 – 4.55 (1H, m), 6.76 (1H, dd), 7.01 (1H, d), 7.34 (1H, d)

Intermediate Preparation C

4-(3-Chloro-4-fluoro-phenoxy)-piperidine

DEAD (0.43ml) was added to a solution of triphenylphosphine (0.72g), 3-chloro-4-fluorophenol (0.403g) and 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (0.5g) in THF at room temperature (RT). The resulting mixture was stirred overnight, HCl in dioxan (2ml of 4M) was added and the mixture stirred at RT overnight. The mixture was then evaporated to dryness and triethylamine (5ml) was added. The mixture was evaporated and the residue was dissolved in methanol (10ml), placed onto a SCX cartridge (Varian, 10g, SCX cartridge available from International Sorbent Technology Isolute® Flash SCX-2) and eluted: first with methanol then with 10%NH₃ in methanol. The basic fractions were combined and evaporated to give the product as an oil (0.6g).

¹H NMR (299.946 MHz, DMSO-D₆) δ 1.34 - 1.46 (2H, m), 1.83 - 1.91 (2H, m), 2.53 - 2.59 (2H, m), 2.87 - 2.96 (2H, m), 3.22 - 3.39 (1H, m), 4.39 (1H, septet), 6.92 - 6.98 (1H, m), 7.17 - 7.20 (1H, m), 7.30 (1H, t).

The following intermediates were prepared in similar manner to this preparative method:

	MS: (M+H)
4-(4-chloro-2-methyl-phenoxy)-piperidine	226/228
4-(4-chloro-3-fluoro-phenoxy)-piperidine	230/232
4-(4-chloro-2-methoxy-phenoxy)-piperidine	242/244
4-(4-fluoro-2-methoxy-phenoxy)-piperidine	226
4-(4-methoxy-phenoxy)-piperidine	208
4-p-tolyloxy-piperidine	192
4-(4-chloro-3-methyl-phenoxy)-piperidine	226/228
4-(4-chloro-phenoxy)-piperidine	212/214
4-(4-fluoro-phenoxy)-piperidine	196

4-(2,4-dichloro-phenoxy)-piperidine	246/248
4-(2-chloro-4-fluoro-phenoxy)-piperidine	230/232
4-(2,4-difluoro-phenoxy)-piperidine	214
4-(4-chloro-2-fluoro-phenoxy)-piperidine	230/232
4-(4-fluoro-2-methyl-phenoxy)-piperidine	210
4-(4-chloro-2,6-dimethyl-phenoxy)-piperidine	240/242
4-(2,3-dichloro-phenoxy)-piperidine	246/248
4-(2,5-dichloro-phenoxy)-piperidine	246/248
4-(2-chloro-4-methyl-phenoxy)-piperidine	226/228
4-(2-chloro-5-methyl-phenoxy)-piperidine	226/228
4-(2-chloro-6-methyl-phenoxy)-piperidine	226/228
4-(4-chloro-2-ethyl-phenoxy)-piperidine	240/242
7-(piperidin-4-yloxy)-quinoline	229
4-(2-tert-butyl-phenoxy)-piperidine	234
4-(indan-5-yloxy)-piperidine	218
4-(4-chloro-2-cyclohexyl-phenoxy)-piperidine	294/296
5-chloro-2-(piperidin-4-yloxy)-benzamide	255/257
4-(4-chloro-2-isoxazol-5-yl-phenoxy)-piperidine	279/281
4-(5-chloro-2-methyl-phenoxy)-piperidine	226/228
4-phenoxy-piperidine	178
4-(2,4-dichloro-6-methyl-phenoxy)-piperidine	260/262
4-(3-chloro-4-methyl-phenoxy)-piperidine	226/228
5-chloro-2-(piperidin-4-yloxy)-benzonitrile	237/239
4-(2,4-dichloro-3-methyl-phenoxy)-piperidine	260/262
4-(2-ethyl-4-fluoro-phenoxy)-piperidine	224
4-(4-methanesulfonyl-phenoxy)-piperidine	297
4-(3,4-dichloro-2-methylphenoxy)-piperidine	260/262

Intermediate Preparation D

3-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]propylamine

Step a: 1,1-dimethylethyl [3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]propyl]-carbamate

- 5 4-(3,4-Dichlorophenoxy)piperidine (10g) was dissolved in *N,N*-dimethylformamide (DMF; 50ml) and triethylamine (14.8ml) was added. 1,1-Dimethylethyl (3-bromopropyl)-carbamate (10g) was added and the solution was stirred at room temperature for 24 hrs. The solvent was evaporated and the resulting solid was dissolved in ethyl acetate and water was added, the organic phase was separated, dried with MgSO_4 and evaporated to give the subtitle compound as a solid (17.51g).

10 M^+ : ESI (+ve): 403/405 (M+H)

Step b: 4-(3,4-dichlorophenoxy)-1-piperidinepropanamine

- The product from Step (a) (2g) was dissolved in dioxane (100ml) and 6N HCl (100ml) was added. After 18 hours at room temperature the solvent was evaporated and the resultant solid was dissolved in aqueous NaOH (2M) to pH 11. The solution was extracted
15 with ethyl acetate, the organic phase was dried (MgSO_4) and evaporated to leave the title compound as an oil (1.1g).

M^+ : ESI (+ve): 303/305 (M+H)

Intermediate Preparation E

4-(3,4-Dichlorophenoxy)-1-piperidineethanamine

- 20 Step a: 1,1-dimethylethyl [2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]-carbamate

- 4-(3,4-Dichlorophenoxy)piperidine (8.6g) was dissolved in DMF (60ml) and triethylamine (12ml) was added. 1,1-Dimethylethyl (2-bromoethyl)-carbamate (7.8g) was added and the solution was stirred at room temperature for 12 hours. Diethyl ether/water (1:1 500ml) was added and the organic phase was separated, dried (MgSO_4) and
25 evaporated. Purification by chromatography (dichloromethane: methanol: NH_3 (aq) 98.5:1:0.5) gave the subtitle compound (10g).

MS: APCI (+ve): 389/391 (M+H)

Step b: 4-(3,4-dichlorophenoxy)-1-piperidineethanamine

- The product from Step a (10g) was dissolved in dichloromethane (200ml) and
30 trifluoroacetic acid (100ml) was added. After 12 hours at room temperature the solvent was evaporated and the resultant solid was washed with diethyl ether and filtered. The solid was dissolved in H_2O , made alkaline with NaOH (2N) to pH 11. The solution was

extracted with dichloromethane, the organic phase was dried (MgSO_4), filtered and evaporated to give the subtitle compound (3.5g).

MS: APCI (+ve): 289/291 (M+H)

Intermediate Preparation F

5 4-(3,4-dichlorophenoxy)-1-piperidineethanesulfonamide

a) 4-(3,4-dichlorophenoxy)-1-piperidineethanesulfonic acid, sodium salt

Vinylsulfonic acid sodium salt (3.3mL of 30% solution in H_2O) was added to 4-(3,4-dichlorophenoxy)-piperidine (2.46g) and the resulting mixture was heated overnight at reflux. The solvents were evaporated to give the subtitle compound (3.5g).

10 MS $[\text{M}+\text{H}]^+$ (ES+) 354/356

b) 4-(3,4-dichlorophenoxy)-1-piperidineethanesulfonyl chloride

4-(3,4-dichlorophenoxy)-1-piperidineethanesulfonic acid, sodium salt (3.5g) was dissolved in dichloromethane (5mL). Thionyl chloride (5mL) was added and the reaction mixture was heated under reflux for 72h. The solvents were evaporated to give the subtitle

15 compound (4.2g)

A small aliquot was dissolved in methanol and gave methyl-4-(3,4-dichlorophenoxy)-1-piperidineethanesulfonate.

MS $[\text{M}+\text{H}]^+$ (ES+) 368/370

c) 4-(3,4-dichlorophenoxy)-1-piperidineethanesulfonamide

20 Ammonia in 1,4-dioxane (5mL of 0.5M) was added to 4-(3,4-dichlorophenoxy)-1-piperidineethanesulfonyl chloride (2g) and the mixture was stirred at room temperature for 2 h. The solvents were evaporated and the residue was chromatographed eluting with dichloromethane : methanol : ammonia (94 : 5 : 1) to give the title compound (0.14g).

MS $[\text{M}+\text{H}]^+$ (ES+) 353/355

25

Intermediate Preparation G

4-methyl-N-(1-oxo-2-propenyl)-benzenesulfonamide

Acryloyl chloride (0.26mL) and p-toluenesulfonamide (0.50g) were dissolved in dichloromethane (5mL) and triethylamine (0.46mL) was added. The reaction mixture was stirred for 3h and NaOH solution (2M, 5mL) was added. The organic layer was separated, the aqueous layer was acidified with HCl (2M) and extracted with dichloromethane. The organic layers were combined, dried over MgSO_4 and evaporated to give the subtitle compound (0.14g)

30

MS $[\text{M}+\text{H}]^+$ (ES+) 225

Example 1

This Example illustrates the preparation of *N*-[[[2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-4-methyl-benzenesulfonamide, which conforms to formula (Ia).

To a solution of 4-(3,4-dichlorophenoxy)-1-piperidineethanamine (WO00/58305) (0.134g) in dichloromethane was added 4-methyl-benzenesulfonyl isocyanate (0.092g) dropwise and the reaction was stirred under nitrogen for 2 hours. The solvent was removed under reduced pressure and the resulting product was purified by RPHPLC (XTerra Waters column; gradient, 90% 0.2% aq ammonia / acetonitrile decreasing to 5% over 10 mins). Recrystallisation of the product from ethanol/ dichloromethane, gave the title compound (0.046g; MS $[M+H]^+$ (ES+) 486/488; m.pt. 179.6-180.3°C).

^1H NMR (399.98 MHz, CD_3OD) δ 1.68 - 1.78 (m, 2H), 1.93 - 2.00 (m, 2H), 2.32 - 2.39 (m, 2H), 2.35 (s, 3H), 2.41 - 2.46 (m, 2H), 2.67 - 2.75 (m, 2H), 3.17 - 3.22 (m, 2H), 4.34 - 4.40 (m, 1H), 6.86 - 6.89 (m, 1H), 7.06 - 7.08 (m, 1H), 7.21 - 7.25 (m, 2H), 7.36 - 7.39 (m, 1H), 7.75 - 7.78 (m, 2H); plus 1 drop of 30% NaOD in D_2O .

The compounds of Examples 2-16 (see table below; all compounds of formula (Ia)) were prepared following the method of Example 1 using the appropriate amine and sulfonylisocyanate.

EXAMPLE 17

N-[[[2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-3-(trifluoromethyl)-benzenesulfonamide (an example of a compound of formula (Ia)) *p*-Nitrophenylchloroformate (0.11g) was dissolved in dichloromethane (5ml). DMAP (67mg) was added followed after 2 min by 3-trifluoromethylbenzenesulfonamide (0.13g). Triethylamine (0.10ml) was added followed by a solution of 4-(3,4-dichlorophenoxy)-1-piperidineethanamine (0.15g) in dichloromethane (1ml). The resulting solution was stirred for 40h. The solvents were evaporated and the residue was purified by HPLC (Waters XTerra® column, 0.2% aq ammonia : acetonitrile gradient 75% - 25% aq) to give the title compound (93mg).
m. pt. 194-201°C
MS $[M+H]^+$ (ES+) 540/542

¹H NMR δ (DMSO) 1.64 - 1.82 (2H, m), 1.92 - 2.05 (2H, m), 2.56 - 2.70 (5H, m), 3.15 (2H, t), 4.45 - 4.54 (1H, m), 6.97 (1H, dd), 7.22 (1H, d), 7.47 (1H, d), 7.75 (1H, t), 7.90 (1H, d).

5

EXAMPLE 18

N-benzoyl-N'-[3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]propyl]-sulfamide (an example of a compound of formula (Ib))

4-(3,4-Dichlorophenoxy)-1-piperidineethanamine (0.16g) was dissolved in dichloromethane (2ml) and triethylamine (88 μ l) was added. Benzoylsulfamoyl chloride (0.13g) was added and the solution was stirred for 16h. The solvent was evaporated and the residue was purified by HPLC (ammonium acetate : acetonitrile 95% to 5% aq) to give the title compound (6mg).

m. pt. 93-106°C

MS [M+H]⁺ (ES+) 486/490

¹H NMR δ (CD₃OD) 1.95 (2H, quintet), 2.00 - 2.11 (2H, m), 2.17 - 2.28 (2H, m), 3.16 (2H, t), 3.16 - 3.22 (2H, m), 4.54 - 4.60 (1H, m), 4.63 - 4.68 (1H, m), 6.95 (1H, dd), 7.20 (1H, d), 7.34 - 7.50 (4H, m), 7.98 - 8.02 (2H, m).

EXAMPLE 19

N-(2-Chlorobenzoyl)-4-(3,4-dichlorophenoxy)-1-piperidineethanesulfonamide (an example of a compound of formula (Id))

4-(3,4-Dichlorophenoxy)-1-piperidineethanesulfonamide (0.1g), EDCI (0.108g), HOBT (40mg), DMAP (40mg) and 2-chlorobenzoic acid (88mg) were dissolved in dichloromethane (5mL) and triethylamine (0.5mL) was added. The reaction mixture was stirred for 17h. The solvents were evaporated. The residue was purified by HPLC (gradient Ammonium acetate/Acetonitrile 95% to 25% ; Xterra column) to give the subtitle compound (40mg)

m. pt. 237-239°C

MS [M+H]⁺ (ES+) 492/494/496

¹H NMR (399.98 MHz) δ (CD₃OD) 1.73 - 1.84 (2H, m), 2.02 (2H, dt), 2.48 (2H, t), 2.81 (2H, t), 2.96 (2H, dd), 3.55 (2H, dd), 4.43 (1H, t), 6.90 (1H, dd), 7.10 (1H, d), 7.25 - 7.33 (2H, m), 7.35 - 7.39 (2H, m), 7.48 - 7.53 (1H, m)

EXAMPLE 20

N-[3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxopropyl]-4-methylbenzenesulfonamide (an example of a compound of formula (Ic))

4-Methyl-*N*-(1-oxo-2-propenyl)-benzenesulfonamide (0.140g) was dissolved in THF (10mL) and 4-(3,4-dichlorophenoxy)-piperidine (0.120g) and NaOH (0.080g) were added. The reaction mixture was stirred for 72h. The solvents were evaporated. The residue was purified by HPLC (gradient Ammonium acetate/Acetonitrile 95% to 5% ; Xterra column) to give the title compound (40mg)
m. pt. 177-179°C

MS [M+H]⁺ (ES+) 471/473

¹H NMR δ (CD₃OD) 1.97 - 2.09 (2H, m), 2.09 - 2.21 (2H, m), 2.38 (3H, s), 2.54 (2H, t), 3.15 - 3.29 (6H, m), 4.64 - 4.71 (1H, m), 6.98 (1H, dd), 7.23 (1H, d), 7.28 (2H, dd), 7.44 (1H, d), 7.82 (2H, dd)

EXAMPLE 21

N-[4-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-4-methylbenzenesulfonamide (an example of a compound of formula (Ic))

4-(3,4-Dichlorophenoxy)-1-piperidinebutanoic acid hydrochloride (0.250g) was dissolved in dichloromethane (10mL) containing p-toluenesulfonamide (0.142g), dimethylaminopyridine (92mg) and EDCI (0.158g) were added. The solution was stirred at room temperature for 4 days. The solvent was evaporated. The crude product was dried *in vacuo* and then purified by HPLC (at column dilution, gradient ammonium acetate/acetonitrile 75% to 5% ; Waters Xterra® column) and to give the title compound (42mg).

MS [M+H]⁺ (ES+) 485/487

¹H NMR (299.946 MHz) δ (DMSO) 1.71 (2H, quintet), 1.79 - 1.93 (2H, m), 2.05 - 2.17 (2H, m), 2.06 - 2.35 (2H, m), 2.35 (3H, s), 2.79 (2H, t), 2.82 - 2.92 (2H, m), 3.00 - 3.09 (2H, m), 4.58 - 4.67 (1H, m), 7.04 (1H, dd), 7.29 (2H, d), 7.33 (1H, d), 7.53 (1H, d), 7.72 (2H, d)

The compounds of Examples 22-34 (see table below; all compounds of formula (Ic)) were prepared following the method of Example 21 using the appropriate sulfonamides.

Example (purification)	Compound	MS [M+H] ⁺ (BS+)	¹ H NMR	m.pt. (°C)
2 recrystallised from DMSO	<i>N</i> -[[[3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]propyl]amino]carbonyl]-4-methyl-benzenesulfonamide	500/502	(CD ₃ OD) 1.58 - 1.67 (m, 2H), 1.71 - 1.80 (m, 2H), 1.93 - 2.01 (m, 2H), 2.28 - 2.37 (m, 4H), 2.35 (s, 3H), 2.63 - 2.71 (m, 2H), 3.04 - 3.10 (m, 2H), 4.36 - 4.42 (m, 1H), 6.86 - 6.90 (m, 1H), 7.07 - 7.09 (m, 1H), 7.21 - 7.25 (m, 2H), 7.38 (d, 1H), 7.75 - 7.78 (m, 2H); plus 1 drop of NaOD (30%) in D ₂ O	200
3 HPLC in aqueous ammonium acetate - acetonitrile	(<i>R</i>) <i>N</i> -[[[3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-2-hydroxypropyl]amino]carbonyl]-4-methyl-benzenesulfonamide	516/518	(DMSO) 1.54 - 1.66 (2H, m), 1.84 - 1.93 (2H, m), 2.21 - 2.28 (2H, m), 2.28 - 2.32 (1H, m), 2.35 (3H, s), 2.62 - 2.73 (2H, m), 2.85 - 2.93 (1H, m), 3.07 (1H, dt), 3.53 - 3.59 (1H, m), 4.39 - 4.47 (1H, m), 4.81 - 4.97 (1H, m), 6.26 - 6.35 (1H, m), 6.98 (1H, dd), 7.26 (1H, d), 7.31 (2H, d), 7.50 (1H, d), 7.71 (2H, d)	103.5-106
4 HPLC in aqueous TFA - methanol	<i>N</i> -[[[2-[4-(3,4-Dichlorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-4-chloro-benzenesulfonamide trifluoroacetate salt	508/510	(CDCl ₃) 2.02 - 2.15 (2H, m), 2.17 - 2.35 (2H, m), 2.99 - 3.22 (4H, m), 3.27 - 3.45 (2H, m), 3.50 - 3.67 (2H, m), 4.52 - 4.63 (1H, m), 6.71 - 6.78 (1H, m), 6.97 - 7.02 (1H, m), 7.35 (1H, d), 7.42 - 7.48 (2H, m), 7.78 - 7.89 (1H, m), 7.89 - 7.99 (2H, m)	106-108

5	N-[[[2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-2-methyl-benzenesulfonamide	486/488	(DMSO) 1.49 - 1.69 (2H, m), 1.79 - 1.99 (2H, m), 2.25 - 2.41 (6H, m), 2.68 (3H, bs), 3.07 (3H, s), 4.39 - 4.51 (1H, m), 6.35 - 6.45 (1H, m), 7.00 (1H, d), 7.21 - 7.42 (3H, m), 7.51 (2H, d), 7.88 (1H, s)	178-179
6	4-chloro-N-[[[2-[4-(3,4-difluorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-benzenesulfonamide	474/476	(DMSO) 1.53 - 1.68 (2H, m), 1.80 - 1.98 (2H, m), 1.94 - 2.10 (1H, m), 2.71 - 2.88 (1H, m), 3.02 - 3.16 (3H, m), 3.22 - 3.43 (4H, m), 6.76 - 6.88 (1H, m), 7.05 - 7.20 (1H, m), 7.34 (1H, dd), 7.46 - 7.62 (2H, m), 7.83 (2H, d)	206-207
7	N-[[[2-[4-(3,4-difluorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-benzenesulfonamide	440	(DMSO) 1.51 - 1.69 (2H, m), 1.82 - 2.01 (2H, m), 2.20 - 2.43 (4H, m), 2.64 - 2.81 (2H, m), 3.00 - 3.18 (2H, m), 4.31 - 4.48 (1H, m), 6.40 - 6.54 (1H, m), 6.72 - 6.88 (1H, m), 7.03 - 7.17 (1H, m), 7.32 (1H, q), 7.38 - 7.69 (3H, m), 7.87 (2H, d)	187-188
8	N-[[[2-[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-4-methyl-benzenesulfonamide	500/502	(DMSO) 1.59 - 1.71 (2H, m), 1.82 - 1.93 (2H, m), 2.27 - 2.35 (4H, m), 2.37 (3H, s), 2.40 (3H, s), 2.60 - 2.72 (2H, m), 3.00 - 3.13 (2H, m), 4.45 - 4.55 (1H, m), 6.45 (1H, s), 7.11 (1H, d), 7.37 (3H, t), 7.76 (2H, d)	203-205

9	N-[[[2-[4-(2-chloro-4-fluorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-4-methyl-benzenesulfonamide	470/472	(DMSO) 1.57 - 1.69 (2H, m), 1.84 - 1.92 (2H, m), 2.21 - 2.36 (3H, m), 2.37 (3H, s), 2.58 - 2.75 (3H, m), 3.00 - 3.12 (2H, m), 4.38 - 4.46 (1H, m), 6.44 (1H, s), 7.15 (1H, td), 7.19 - 7.31 (1H, m), 7.31 - 7.47 (3H, m), 7.76 (2H, d)	150-152
10	4-chloro-N-[[[2-[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-benzenesulfonamide	520/522/524	(DMSO) 1.63 - 1.76 (2H, m), 1.80 - 1.99 (2H, m), 2.04 - 2.35 (2H, m), 2.41 (3H, s), 2.67 - 2.86 (2H, m), 3.10 (2H, s), 6.44 (1H, s), 7.13 (1H, s), 7.37 (1H, d), 7.47 - 7.65 (2H, m), 7.84 (2H, d)s	209-210
11	N-[[[2-[4-(2,4-dichloro-3-methylphenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-2-methyl-benzenesulfonamide	500/502	(DMSO) 1.17 - 1.34 (1H, m), 1.60 - 1.73 (2H, m), 1.81 - 1.93 (2H, m), 2.40 (3H, s), 2.58 (3H, s), 2.64 - 2.76 (3H, m), 3.03 - 3.14 (3H, m), 4.51 (1H, s), 6.41 (1H, s), 7.04 - 7.16 (1H, m), 7.31 - 7.40 (3H, m), 7.52 (1H, s), 7.89 (1H, d)	119-120
12	N-[[[2-[4-(3,4-dichlorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-benzenesulfonamide	472/474	(DMSO) 1.01 - 1.31 (2H, m), 1.48 - 1.66 (1H, m), 1.76 - 2.02 (2H, m), 2.26 - 2.41 (2H, m), 2.67 (2H, quintet), 3.03 - 3.09 (2H, m), 7.00 (1H, s), 7.27 (1H, s), 7.46 - 7.66 (4H, m), 7.84 (2H, s)	183-184

13	2-chloro-N-[[[2-[4-(3,4-difluorophenoxy)-1-piperidinyl]ethyl]amino]carbonyl]-benzenesulfonamide	474/476	(DMSO) 1.50 - 1.75 (2H, m), 1.79 - 2.12 (2H, m), 2.22 - 2.40 (2H, m), 2.73 - 2.88 (3H, m), 3.00 - 3.19 (4H, m), 4.34 - 4.74 (1H, m), 6.27 - 6.39 (1H, m), 6.71 - 6.94 (1H, m), 7.08 - 7.23 (1H, m), 7.29 - 7.59 (4H, m), 7.891 (1H, d)	160-161
14	Starting amine described in EP0903349	526/528	(DMSO) 0.80 (6H, d), 1.19 (2H, d), 1.46 (3H, s), 1.66 - 1.76 (1H, m), 1.83 - 1.94 (2H, m), 2.20 - 2.38 (5H, m), 2.49 (2H, d), 2.79 (2H, d), 3.67 (1H, s), 7.08 (1H, dd), 7.18 (2H, d), 7.30 (1H, d), 7.41 (1H, d), 7.75 (2H, d)	120-126
15	4-chloro-N-[[[4-(3,4-dichlorophenyl)methyl]-1-piperidinyl]methyl]-2-methylpropyl]amino]carbonyl]-4-methyl-benzenesulfonamide	547/549/551	(CD ₃ OD) 0.77 - 0.84 (6H, m), 1.18 (2H, t), 1.40 - 1.55 (3H, m), 1.71 (1H, dd), 1.81 - 1.96 (2H, m), 2.21 - 2.37 (2H, m), 2.49 (2H, d), 2.79 (2H, t), 3.66 (1H, s), 7.08 (1H, dd), 7.31 (1H, d), 7.39 (3H, dd), 7.85 (2H, d)	182-188
16	N-[[[2-[4-(3,4-dichlorophenyl)methyl]-1-piperidinyl]ethyl]amino]carbonyl]-4-methyl-benzenesulfonamide	484/486	(CD ₃ OD) 1.19 - 1.32 (2H, m), 1.45-1.59 (3H, m), 1.93 (2H, t), 2.35 (3H, s), 2.37 (2H, t), 2.51 (2H, d), 2.86 (2H, d), 3.13-3.20 (2H, m), 7.08 (1H, dd), 7.22 (2H, d), 7.30 (1H, d), 7.39 (1H, d), 7.75 (2H, dd)	

22	4-chloro-N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-benzenesulfonamide	506/508/510	(CD ₃ OD) 1.66 - 1.80 (4H, m), 1.91 - 2.02 (2H, m), 2.13 (2H, t), 2.21 - 2.36 (4H, m), 2.68 (2H, s), 4.37 (1H, dt), 6.88 (1H, dd), 7.08 (1H, d), 7.37 (1H, d), 7.45 (2H, d), 7.88 (2H, dt)	208-211
23	3,5-dichloro-N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-benzenesulfonamide	539/541/543		
24	N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-3-(trifluoromethyl)-benzenesulfonamide	539/541		
25	methyl 2-[[[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]amino]sulfonyl]-benzoate	529/531		
26	5-chloro-N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-2-thiophenesulfonamide	511/513/515		
27	5-bromo-N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-2-thiophenesulfonamide	555/557/559		

28	4,5-dichloro-N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-2-thiophenesulfonamide	545/547/549		
29	2,5-dichloro-N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-3-thiophenesulfonamide	545/547/549		
30	4-bromo-N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-2-thiophenesulfonamide	555/557/559		
31	6-bromo-N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-3-pyridinesulfonamide	550/552/554		
32	N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-2,5-difluoro-benzenesulfonamide	507/509		
33	N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-2,4,5-trifluoro-benzenesulfonamide	525/527		

34	5-chloro-N-[4-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-1-oxobutyl]-2,4-difluorobenzenesulfonamide	541/543/545	
----	--------------------------------------------------------------------------------------------------	-------------	--

Example 22Pharmacological Analysis: Calcium flux [Ca^{2+}]_i assayHuman eosinophils

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended ($5 \times 10^6 \text{ ml}^{-1}$) and loaded with $5 \mu\text{M}$ FLUO-3/AM + Pluronic F127 $2.2 \mu\text{l/ml}$ (Molecular Probes) in low potassium solution (LKS; NaCl 118mM, MgSO_4 0.8mM, glucose 5.5mM, Na_2CO_3 8.5mM, KCl 5mM, HEPES 20mM, CaCl_2 1.8mM, BSA 0.1%, pH 7.4) for one hour at room temperature. After loading, cells were centrifuged at 200g for 5min and resuspended in LKS at $2.5 \times 10^6 \text{ ml}^{-1}$. The cells were then transferred to 96 well FLIPr plates (Poly-D-Lysine plates from Becton Dickinson pre-incubated with $5 \mu\text{M}$ fibronectin for two hours) at $25 \mu\text{l/well}$. The plate was centrifuged at 200g for 5min and the cells were washed twice with LKS ($200 \mu\text{l}$; room temperature).

A compound of the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A_{50} concentration of eotaxin and the transient increase in fluo-3 fluorescence ($I_{\text{Ex}} = 490\text{nm}$ and $I_{\text{Em}} = 520\text{nm}$) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

Human eosinophil chemotaxis

Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., *J. Immunol. Methods*, 1991, 145, 105-110). The cells were resuspended at $10 \times 10^6 \text{ ml}^{-1}$ in RPMI containing 200 IU/ml penicillin, $200 \mu\text{g/ml}$ streptomycin sulfate and supplemented with 10% HIFCS, at room temperature.

Eosinophils ($700 \mu\text{l}$) were pre-incubated for 15 mins at 37°C with $7 \mu\text{l}$ of either vehicle or compound ($100\times$ required final concentration in 10% DMSO). The chemotaxis plate (ChemoTx, $3 \mu\text{m}$ pore, Neuroprobe) was loaded by adding $28 \mu\text{l}$ of a concentration of eotaxin (0.1 to 100nM) containing a concentration of a compound according to the Examples or solvent to the lower wells of the chemotaxis plate. The filter was then placed over the wells and $25 \mu\text{l}$ of eosinophil suspension were added to the top of the filter. The plate was incubated for 1 hr at 37°C in a humidified incubator with a 95% air/5% CO_2 atmosphere to allow chemotaxis.

The medium, containing cells that had not migrated, was carefully aspirated from above the filter and discarded. The filter was washed once with phosphate buffered saline (PBS) containing 5 mM EDTA to remove any adherent cells. Cells that had migrated through the filter were pelleted by centrifugation (300xg for 5 mins at room temperature) and the filter removed and the supernatant transferred to each well of a 96-well plate (Costar). The pelleted cells were lysed by the addition of 28µl of PBS containing 0.5% Triton x100 followed by two cycles of freeze/thawing. The cell lysate was then added to the supernatant. The number of eosinophils migrating was quantified according to the method of Strath et al., *J. Immunol. Methods*, 1985, 83, 209 by measuring eosinophil peroxidase activity in the supernatant.

The compound of Example 1 was found to be an antagonist of the eotaxin mediated human eosinophil chemotaxis.

Example 23

Guinea-pig isolated trachea

(See for example, Harrison, R.W.S., Carswell, H. & Young, J.M. (1984) *European J. Pharmacol.*, 106, 405-409.)

Male albino Dunkin-Hartley guinea-pigs (250g) were killed by cervical dislocation and the whole trachea removed. After clearing the adherent connective tissue, the trachea was cut into six ring segments each three cartilage bands wide and then suspended in 20ml organ baths containing Krebs-Henseleit solution of the following composition (mM): NaCl 117.6, NaH₂PO₄ 0.9, NaHCO₃ 25.0, MgSO₄ 1.2, KCl 5.4, CaCl₂ 2.6 and glucose 11.1. The buffer was maintained at 37°C and gassed with 5% CO₂ in oxygen. Indomethacin (2.8µM) was added to the Krebs solution to prevent development of smooth muscle tone due to the synthesis of cyclo-oxygenase products. The tracheal rings were suspended between two parallel tungsten wire hooks, one attached to an Ormed beam isometric force transducer and the other to a stationary support in the organ bath. Changes in isometric force were recorded on 2-channel Sekonic flat bed chart recorders.

Experimental protocols

At the beginning of each experiment a force of 1g was applied to the tissues and this was reinstated over a 60 minute equilibration period until a steady resting tone was achieved. Subsequently, a cumulative histamine concentration effect (E/[A]) curve was constructed at 0.5 log₁₀ unit increments, in each tissue. The tissues were then washed and approximately 30

minutes later, test compound or vehicle (20% DMSO) was added. Following an incubation period of 60 minutes a second E/[A] curve was performed to histamine.

Contraction responses were recorded as a percentage of the first curve maximum.

Data analysis


- 5 Experimental E/[A] curve data were analysed for the purposes of estimating the potencies ($p[A_{50}]$ values) of histamine in the absence and presence of the test compound. Affinity (pA_2) values of test compounds were subsequently calculated using the following equation:

$$\log(r-1) = \log[B] + pA_2$$

- 10 where $r = [A]_{50}$ in presence of test compound/ $[A]_{50}$ in absence of antagonist and $[B]$ is the concentration of test compound. The compound of Example 1 was found to be an H1 antagonist.

CLAIMS

1. A compound of formula (I):



wherein:

T is C(O) or S(O)₂;

W is C(O) or S(O)₂;

X is CH₂, O or NH;

Y is CR¹¹ or N;

n is 0, 1 or 2;

m is 1 or, when Y is CR¹¹ m is 0;

R¹ is optionally substituted aryl or optionally substituted heterocyclyl;

R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are, independently, hydrogen or C₁₋₆ alkyl; wherein these alkyl groups are optionally substituted by OH, provided that when Y is N then

R⁸ does not have a hydroxy on the carbon atom bonded to Y;

or R² and R³, R⁴ and R⁵, or R⁶ and R⁷, together with the atom to which they are attached, form a 3-7 membered carbocyclic ring;

R⁴ may additionally be OH or C₁₋₆ alkoxy;

when Y is CR¹¹ the group R⁶ may additionally be OH or C₁₋₆ alkoxy;

provided that only one R⁴ or R⁶ is OH;

R⁹ is hydrogen or C₁₋₆ alkyl;

R¹⁰ is alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heterocyclyl;

R¹¹ is hydrogen or C₁₋₆ alkyl;

wherein the foregoing aryl and heterocyclyl moieties are optionally substituted by:

halogen, cyano, nitro, hydroxy, oxo, S(O)_pR¹², OC(O)NR¹³R¹⁴, NR¹⁵R¹⁶,

NR¹⁷C(O)R¹⁸, NR¹⁹C(O)NR²⁰R²¹, S(O)₂NR²²R²³, NR²⁴S(O)₂R²⁵, C(O)NR²⁶R²⁷,

C(O)R²⁸, CO₂R²⁹, NR³⁰CO₂R³¹, C₁₋₆ alkyl, CF₃, C₁₋₆ alkoxy(C₁₋₆)alkyl, C₁₋₆ alkoxy,

OCF₃, C₁₋₆ alkoxy(C₁₋₆)alkoxy, C₁₋₆ alkylthio, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀

cycloalkyl (itself optionally substituted by C₁₋₄ alkyl or oxo), methylenedioxy,

difluoromethylenedioxy, phenyl, phenyl(C₁₋₄)alkyl, phenoxy, phenylthio,
 phenyl(C₁₋₄)alkoxy, heteroaryl, heteroaryl(C₁₋₄)alkyl, heteroaryloxy or
 heteroaryl(C₁₋₄)alkoxy; wherein any of the immediately foregoing phenyl and
 heteroaryl moieties are optionally substituted with halogen, hydroxy, nitro,
 5 S(O)_q(C₁₋₄ alkyl), S(O)₂NH₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄
 alkyl), CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl),
 C(O)(C₁₋₄ alkyl), CF₃ or OCF₃;

p and q are, independently, 0, 1 or 2;

10 R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁶, R²⁷, R²⁸, R²⁹, and R³⁰
 are, independently, hydrogen, C₁₋₆ alkyl (optionally substituted by halogen,
 hydroxy or C₃₋₁₀ cycloalkyl), CH₂(C₂₋₆ alkenyl), phenyl (itself optionally substituted
 by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, S(O)₂(C₁₋₄ alkyl),
 S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy,
 C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl),
 15 NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or
 heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄
 alkyl), N(C₁₋₄ alkyl)₂, S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl),
 S(O)₂N(C₁₋₄ alkyl)₂, cyano, C₁₋₄ alkyl, C₁₋₄ alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl),
 C(O)N(C₁₋₄ alkyl)₂, CO₂H, CO₂(C₁₋₄ alkyl), NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄
 20 alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃);

alternatively NR¹³R¹⁴, NR¹⁵R¹⁶, NR²⁰R²¹, NR²²R²³, NR²⁶R²⁷, and N(C₁₋₄ alkyl)₂
 may, independently, form a 4-7 membered heterocyclic ring, azetidine, pyrrolidine,
 piperidine, azepine, 1,4-morpholine or 1,4-piperazine, the latter optionally
 substituted by C₁₋₄alkyl on the distal nitrogen;

25 R¹², R²⁵ and R³¹ are, independently, C₁₋₆ alkyl (optionally substituted by halogen,
 hydroxy or C₃₋₁₀ cycloalkyl), CH₂(C₂₋₆ alkenyl), phenyl (itself optionally substituted
 by halogen, hydroxy, nitro, NH₂, NH(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂ (and these alkyl
 groups may join to form a ring as described for R¹³ and R¹⁴ above), S(O)₂(C₁₋₄
 alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl)₂ (and these alkyl groups
 30 may join to form a ring as described for R¹³ and R¹⁴ above), cyano, C₁₋₄ alkyl, C₁₋₄
 alkoxy, C(O)NH₂, C(O)NH(C₁₋₄ alkyl), C(O)N(C₁₋₄ alkyl)₂ (and these alkyl groups
 may join to form a ring as described for R¹³ and R¹⁴ above), CO₂H, CO₂(C₁₋₄ alkyl),
 NHC(O)(C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃) or

heterocyclyl (itself optionally substituted by halogen, hydroxy, nitro, NH_2 , $\text{NH}(\text{C}_{1-4}$ alkyl), $\text{N}(\text{C}_{1-4}$ alkyl) $_2$ (and these alkyl groups may join to form a ring as described for R^{13} and R^{14} above), $\text{S}(\text{O})_2(\text{C}_{1-4}$ alkyl), $\text{S}(\text{O})_2\text{NH}_2$, $\text{S}(\text{O})_2\text{NH}(\text{C}_{1-4}$ alkyl), $\text{S}(\text{O})_2\text{N}(\text{C}_{1-4}$ alkyl) $_2$ (and these alkyl groups may join to form a ring as described for R^{13} and R^{14} above), cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $\text{C}(\text{O})\text{NH}_2$, $\text{C}(\text{O})\text{NH}(\text{C}_{1-4}$ alkyl), $\text{C}(\text{O})\text{N}(\text{C}_{1-4}$ alkyl) $_2$ (and these alkyl groups may join to form a ring as described for R^{13} and R^{14} above), CO_2H , $\text{CO}_2(\text{C}_{1-4}$ alkyl), $\text{NHC}(\text{O})(\text{C}_{1-4}$ alkyl), $\text{NHS}(\text{O})_2(\text{C}_{1-4}$ alkyl), $\text{C}(\text{O})(\text{C}_{1-4}$ alkyl), CF_3 or OCF_3); or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof.

2. A compound as claimed in claim 1 wherein X is O.

3. A compound as claimed in claim 1 or 2 wherein R^1 is phenyl substituted with one or more of fluorine, chlorine, C_{1-4} alkyl or C_{1-4} alkoxy.

4. A compound as claimed in claim 1, 2 or 3 wherein one of T and W is $\text{C}(\text{O})$ and the other is $\text{S}(\text{O})_2$.

5. A compound as claimed in claim 1, 2, 3 or 4 wherein T is $\text{C}(\text{O})$.

6. A compound as claimed in claim 1, 2, 3, 4 or 5 wherein W is $\text{S}(\text{O})_2$.

7. A compound as claimed in claim 1, 2, 3, 4, 5 or 6 wherein Y is CH.

8. A compound as claimed in claim 1, 2, 3, 4, 5, 6 or 7 wherein m and n are both 1.


9. A compound as claimed in claim 1, 2, 3, 4, 5, 6, 7 or 8 wherein R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 and R^9 are all hydrogen.

10. A compound as claimed in claim 1, 2, 3, 4, 5, 6, 7, 8 or 9 wherein R^{10} is substituted phenyl, the substituents being chosen from those provided in claim 1.

11. A compound as claimed in claim 10 wherein R^{10} is phenyl optionally substituted by: halo, hydroxy, nitro, cyano, amino, C_{1-4} alkyl (itself optionally substituted by $S(O)_2(C_{1-4}$ alkyl), $S(O)_2$ phenyl), C_{1-4} alkoxy, $S(O)_kR^{32}$ (wherein k is 0, 1 or 2; and R^{32} is C_{1-4} alkyl, C_{1-4} hydroxyalkyl, C_{3-7} cycloalkyl(C_{1-4} alkyl) or phenyl), $C(O)NH_2$, $NHS(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl) or $S(O)_2N(C_{1-4} alkyl)_2$ (and these alkyl groups may join to form a ring).


12. A process for preparing a compound of formula (I) as claimed in claim 1, the process comprising:

- a. when R^9 is hydrogen, T is $C(O)$ and Y is N , reacting a compound of formula (II):




with an isocyanate of formula $R^{10}WN=C=O$ in the presence of a suitable solvent at a suitable temperature;

- b. when R^9 is hydrogen, T is $C(O)$ and Y is N , reacting a compound of formula (II) with the adduct formed between p -nitrophenyl chloroformate and an amide $R^{10}WNH_2$, in the presence of dimethylaminopyridine;
- c. when R^9 is hydrogen, T is $S(O)_2$, W is $C(O)$ and Y is N , reacting a compound of formula (IX):




with a compound of formula (II) in the presence of a suitable base in a suitable solvent at a suitable temperature;

- d. when T and W are both $S(O)_2$ and Y is N , reacting a compound of formula (X):



with a sulfonamide of formula $R^{10}S(O)_2NHR^9$ in the presence of a base in a suitable solvent at a temperature in the range 50-110°C;

- e. when T and W are both $S(O)_2$ and Y is N, reacting a compound of formula (Xa):




5

with a sulfonyl chloride of formula $R^{10}SO_2Cl$ in the presence of a base, in a suitable solvent at a temperature in the range $50-110^\circ C$;

- f. when T is $S(O)_2$, W is CO and Y is N, reacting a compound of formula (Xa) with an acid $R^{10}COOH$ in the presence of an appropriate coupling agent in a suitable solvent;

10


- g. when R^2 is hydrogen, T is $C(O)$, W is $S(O)_2$ and Y is CR^{11} , by firstly hydrolysing a compound of formula (XI):



wherein suitable ester groups include C_{1-6} alkyl groups, and reacting the product so formed with $R^{10}S(O)_2NHR^9$ in the presence of an appropriate coupling agent in a suitable solvent;

15

- h. when T and W are both $C(O)$ and Y is CR^{11} , heating a compound of formula (XIV):



in the presence of $R^{10}C(OR')_2N(CH_3)_2$ or $R^{10}C(OR')_3$, wherein R' is methyl or ethyl, or $(OR')_3$ is $(OCH_2)_3CCH_3$; or,

20

- i. when R^9 is alkyl, alkylating a compound of formula (I) where R^9 is H with an appropriate alkylating agent R^9-L , wherein L is a leaving group in the presence of a suitable base in a suitable solvent.

13. A pharmaceutical composition comprising a compound of the formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.
- 5 14. A compound of the formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in therapy.
15. The use of a compound of the formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of
10 a medicament for use in therapy.
16. A method of treating a chemokine mediated disease state in a mammal suffering from, or at risk of, said disease, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of
15 formula (I), or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof, as claimed in claim 1.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/01401

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 211/06, C07D 409/12, C07D 401/12, A61K 31/445, A61P 37/00, A61P 11/06, A61P 31/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM. ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 0220484 A1 (ASTRAZENECA AB), 14 March 2002 (14.03.02)	1-16
	--	
P,X	WO 0230899 A1 (NOVARTIS AG), 18 April 2002 (18.04.02)	1-16
	--	
X	WO 0058305 A1 (ASTRAZENECA AB), 5 October 2000 (05.10.00)	1-16
	--	

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 October 2002

Date of mailing of the international search report

29 -10- 2002

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell/Eö

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/01401

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0661266 A1 (TOA EIYO LTD.), 5 July 1995 (05.07.95), RN 169947-56-2; the claims; the examples	1-15
A	---	16
X	EP 0515240 A1 (ELF SANOFI), 25 November 1992 (25.11.92)	1-15
A	---	16
A	WO 9938514 A1 (MERCK & CO., INC.), 5 August 1999 (05.08.99)	1-16
A	STN International, File CAPLUS, CAPLUS accession no. 1996:113480, Document no. 124:220549, Kharkovskij Farmatsevticheskij Institut: "Piperidylamide of 3,5-dibromo-4-aminobenzene-sulfonylamino succinic acid which produces neuroleptic and diuretic effects"; & SU,A1,1824396, 19930630	1-16

INTERNATIONAL SEARCH REPORT
Information on patent family members

30/09/02

International application No.

PCT/SE 02/01401

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0220484	A1	14/03/02	AU	8458401 A	22/03/02
				GB	0021670 D	00/00/00
WO	0230899	A1	18/04/02	AU	1592802 A	22/04/02
				AU	9560101 A	22/04/02
				GB	0024675 D	00/00/00
				WO	0230898 A	18/04/02
				GB	0106030 D	00/00/00
WO	0058305	A1	05/10/00	AU	4157500 A	16/10/00
				AU	4942599 A	17/01/00
				BR	0009338 A	26/12/01
				CN	1344266 T	10/04/02
				CZ	20013451 A	17/04/02
				EP	1100637 A	23/05/01
				EP	1165545 A	02/01/02
				NO	20014518 A	17/09/01
				SE	9901117 D	00/00/00
				TR	200102800 T	00/00/00
				US	6439018 B	27/08/02
				AU	2013500 A	13/06/00
				EP	1133431 A	19/09/01
				SE	9902194 D	00/00/00
EP	0661266	A1	05/07/95	JP	7242629 A	19/09/95
				US	5728835 A	17/03/98

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE02/01401

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 16
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE02/01401

Claim 16 relates to a method of treatment of the human or animal body by surgery or by therapy/a diagnostic method practised on the human or animal body/Rule 39.1(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT
Information on patent family members

30/09/02

International application No.

PCT/SE 02/01401

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0515240 A1	25/11/92	SE 0515240 T3 AT 158574 T AU 657321 B AU 1591892 A BR 9201655 A CA 2067924 A CS 9201328 A CZ 282919 B DE 69222352 D,T DK 515240 T ES 2109987 T FI 103041 B FI 921950 A FR 2676054 A,B GR 3025277 T HU 65273 A HU 213915 B HU 9201459 D IE 921365 A IL 101762 A JP 3108719 B JP 5140103 A KR 244063 B MX 9202026 A NO 178572 B,C NO 921733 A NZ 242584 A RU 2089547 C US 5411971 A US 5606065 A ZA 9203176 A	15/10/97 09/03/95 05/11/92 15/12/92 04/11/92 18/11/92 12/11/97 09/04/98 11/05/98 01/02/98 00/00/00 04/11/92 06/11/92 27/02/98 02/05/94 28/11/97 00/00/00 04/11/92 16/10/96 13/11/00 08/06/93 02/03/00 01/11/92 15/01/96 04/11/92 27/04/95 10/09/97 02/05/95 25/02/97 28/04/93
WO 9938514 A1	05/08/99	AU 2654399 A CA 2319781 A EP 1052992 A GB 9810890 D JP 2002501898 T US 6132017 A US 6140349 A US 6423303 B	16/08/99 05/08/99 22/11/00 00/00/00 22/01/02 17/10/00 31/10/00 23/07/02